argenx SE (NASDAQ:ARGX) Sees Large Drop in Short Interest

argenx SE (NASDAQ:ARGX) saw a large decline in short interest in March. As of March 31st, there was short interest totalling 1,200,000 shares, a decline of 10.4% from the March 15th total of 1,340,000 shares. Based on an average daily trading volume, of 332,500 shares, the short-interest ratio is presently 3.6 days.

Analysts Set New Price Targets

ARGX has been the topic of a number of research reports. Wells Fargo & Company boosted their price objective on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 20th. Robert W. Baird dropped their price objective on argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. Evercore ISI dropped their price objective on argenx from $594.00 to $436.00 and set an “outperform” rating on the stock in a research note on Thursday, December 21st. Wolfe Research initiated coverage on argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Finally, Raymond James dropped their price objective on argenx from $580.00 to $520.00 and set a “strong-buy” rating on the stock in a research note on Thursday, December 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and an average price target of $530.74.

Institutional Investors Weigh In On argenx

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Steph & Co. increased its holdings in argenx by 27.1% during the 1st quarter. Steph & Co. now owns 413 shares of the company’s stock valued at $163,000 after purchasing an additional 88 shares in the last quarter. Park Avenue Securities LLC increased its holdings in argenx by 20.7% during the 1st quarter. Park Avenue Securities LLC now owns 1,235 shares of the company’s stock valued at $486,000 after purchasing an additional 212 shares in the last quarter. Mather Group LLC. acquired a new stake in argenx during the 1st quarter valued at $38,000. GAMMA Investing LLC increased its holdings in argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after purchasing an additional 63 shares in the last quarter. Finally, Wahed Invest LLC increased its holdings in argenx by 9.6% during the 4th quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after purchasing an additional 40 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Price Performance

argenx stock opened at $370.68 on Wednesday. The company has a market capitalization of $21.98 billion, a PE ratio of -72.12 and a beta of 0.65. argenx has a one year low of $327.73 and a one year high of $550.76. The business has a 50 day simple moving average of $389.50 and a 200 day simple moving average of $422.65.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million for the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same quarter last year, the business earned ($0.70) EPS. Equities analysts anticipate that argenx will post -2 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.